September 16th, 2025
11 a.m. EDT

Parkinson’s Disease (PD) affects more than 6 million people worldwide, yet the gold-standard treatment was approved over 30 years ago^1,2. With a robust early-stage pipeline, the absence of new, transformative treatments is not the result of lack of interest but of the high failure rate following phase II clinical trials³. So, how can developers increase their probability of success?

To propel the field toward its next breakthrough, success hinges on trial designs that reflect the realities of PD’s complexity and accommodate varying patient needs.

In this webinar, our expert speakers will explore essential strategies for executing successful PD clinical trials. Topics will include collaborating with patient advocacy groups, using innovative study designs, selecting the appropriate symptom scales, and protecting study endpoints. At the heart of it all: putting the patient first.

Speakers:

Antonio Hernandez, PsyD – Vice President, Program Strategy, Neuroscience

Melissa Snyder, PhD – Executive Director, Program Strategy, Neuroscience

Sources:

1. “Parkinson’s 101.” The Michael J. Fox Foundation for Parkinson’s Research | Parkinson’s Disease, 2025, www.michaeljfox.org/parkinsons-101.

2. “7 Most Promising Drugs in Parkinson’s Disease Treatment Pipeline.” BioSpace, 10 Dec. 2024, www.biospace.com/press-releases/7-most-promising-drugs-in-parkinsons-disease-treatment-pipeline.

3. McFarthing K, Buff S, Rafaloff G, Pitzer K, Fiske B, Navangul A, Beissert K, Pilcicka A, Fuest R, Wyse RK, Stott SRW. Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2024 Update. J Parkinsons Dis. 2024;14(5):899-912. doi: 10.3233/JPD-240272. PMID: 39031388; PMCID: PMC11307066.